TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Benzinga Logo Benzinga By Business Wire
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

MoonLake Immunotherapeutics faces potential securities fraud lawsuit after announcing disappointing Phase 3 results for its drug candidate sonelokimab, which failed to match competitor's efficacy, causing significant stock price drop.

Insights
REGN   positive

Newest market entrant with Lynozyfic, expanding addressable market in multiple myeloma


MLTX   negative

Stock dropped 89.9% after revealing drug candidate's inefficacy, potential legal action from shareholders, and allegations of misleading investors about product capabilities